Literature DB >> 15014526

Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF.

S Wellmann1, M Guschmann, W Griethe, C Eckert, A von Stackelberg, C Lottaz, E Moderegger, H G Einsiedel, K-U Eckardt, G Henze, K Seeger, Av Stackelberg.   

Abstract

Hypoxia-inducible factor 1 (HIF-1) controls angiogenesis and glycolysis, two leading characteristics of solid tumor invasion, metastasis, and lethality. Increased angiogenesis is also found in the bone marrow (BM) of leukemias. Less is known in leukemia about the role of HIF-1 and vascular endothelial growth factor (VEGF), the most important proangiogenic target gene of HIF-1. We show by immunohistochemistry that the oxygen-regulated component of HIF-1 (HIF-1alpha) is overexpressed in clusters of leukemic cells in BM specimens of childhood acute lymphoblastic leukemia (ALL) and absent in biopsies of normal BM. Half the HIF-1alpha-positive ALL biopsies exhibited VEGF coexpression. Among 96 children with relapsed ALL, diagnostic BM aspirates with high VEGF mRNA levels were associated with a significantly lower probability of event-free survival at 3 years (0.31+/-0.08 vs 0.65+/-0.07, P=0.003). Those with poor molecular response to therapy (evaluated by MRD assessment) had 2.2-fold higher VEGF levels than those responding well to chemotherapy (P=0.005). In conclusion, the data demonstrate activation of the HIF pathway in the BM of ALL patients and indicate that the expression of HIF target genes, such as VEGF, play an important role in leukemia progression, therapy response, and outcome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15014526     DOI: 10.1038/sj.leu.2403332

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  35 in total

1.  Mechanism and Function of Angiogenin in Hematopoietic Malignancy.

Authors:  Kevin A Goncalves; Guo-Fu Hu
Journal:  Zhongguo Sheng Wu Hua Xue Yu Fen Zi Sheng Wu Xue Bao       Date:  2015-12-23

2.  Leukemia stem cells in T-ALL require active Hif1α and Wnt signaling.

Authors:  Vincenzo Giambra; Catherine E Jenkins; Sonya H Lam; Catherine Hoofd; Miriam Belmonte; Xuehai Wang; Sam Gusscott; Deanne Gracias; Andrew P Weng
Journal:  Blood       Date:  2015-05-01       Impact factor: 22.113

Review 3.  Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches.

Authors:  Marina Konopleva; Yoko Tabe; Zhihong Zeng; Michael Andreeff
Journal:  Drug Resist Updat       Date:  2009-07-25       Impact factor: 18.500

4.  Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.

Authors:  Talha Badar; Damian R Handisides; Juliana M Benito; Mary Ann Richie; Gautam Borthakur; Elias Jabbour; Karine Harutyunyan; Sergej Konoplev; Stefan Faderl; Stew Kroll; Michael Andreeff; Tillman Pearce; Hagop M Kantarjian; Jorge E Cortes; Deborah A Thomas; Marina Konopleva
Journal:  Am J Hematol       Date:  2016-06-25       Impact factor: 10.047

Review 5.  Advances in understanding the leukaemia microenvironment.

Authors:  Yoko Tabe; Marina Konopleva
Journal:  Br J Haematol       Date:  2014-01-09       Impact factor: 6.998

Review 6.  Immune-Based Therapies in Acute Leukemia.

Authors:  Matthew T Witkowski; Audrey Lasry; William L Carroll; Iannis Aifantis
Journal:  Trends Cancer       Date:  2019-08-29

Review 7.  Development and maintenance of cancer stem cells under chronic inflammation.

Authors:  Toshihiko Tanno; William Matsui
Journal:  J Nippon Med Sch       Date:  2011       Impact factor: 0.920

8.  Therapeutic targeting of membrane-associated GRP78 in leukemia and lymphoma: preclinical efficacy in vitro and formal toxicity study of BMTP-78 in rodents and primates.

Authors:  D I Staquicini; S D'Angelo; F Ferrara; K Karjalainen; G Sharma; T L Smith; C A Tarleton; D E Jaalouk; A Kuniyasu; W B Baze; B K Chaffee; P W Hanley; K F Barnhart; E Koivunen; S Marchiò; R L Sidman; J E Cortes; H M Kantarjian; W Arap; R Pasqualini
Journal:  Pharmacogenomics J       Date:  2017-12-05       Impact factor: 3.550

9.  Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.

Authors:  Marina Konopleva; Peter F Thall; Cecilia Arana Yi; Gautam Borthakur; Andrew Coveler; Carlos Bueso-Ramos; Juliana Benito; Sergej Konoplev; Yongchuan Gu; Farhad Ravandi; Elias Jabbour; Stefan Faderl; Deborah Thomas; Jorge Cortes; Tapan Kadia; Steven Kornblau; Naval Daver; Naveen Pemmaraju; Hoang Q Nguyen; Jennie Feliu; Hongbo Lu; Caimiao Wei; William R Wilson; Teresa J Melink; John C Gutheil; Michael Andreeff; Elihu H Estey; Hagop Kantarjian
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

Review 10.  Integration of hypoxic HIF-α signaling in blood cancers.

Authors:  L Schito; S Rey; M Konopleva
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.